Disruption and potentiation of latent inhibition by risperidone: The latent inhibition model of atypicalantipsychotic action

Neuropsychopharmacology

Volumn 28, Issue 3, 2003, Pages 499-509

  Weiner, Ina ^a   Schiller, Daniela ^a   Gaisler Salomon, Inna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atypicalantipsychotic drugs; Haloperidol; Latent inhibition; Rat; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL; ARTICLE; CONDITIONING; DRUG EFFECT; INHIBITION (PSYCHOLOGY); MALE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RAT; SCHIZOTYPAL PERSONALITY DISORDER; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CONDITIONING (PSYCHOLOGY); INHIBITION (PSYCHOLOGY); MALE; RATS; RATS, WISTAR; RISPERIDONE; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 0038323855     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300069     Document Type: Article

References (65)

1. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology18: 63-101.
2. Asin KE, Wirtshafter D, Kent EW (1980).The effects of electrolytic median raphe lesions on two measures of latent inhibition.Behav Neur Biol28: 408-417.
3. Bakshi VP, Geyer MA (1995). Antagonism of phen-cyclidine-induced deficits in pre-pulse inhibition by the putative atypical antipsychotic olanzapine.Psychopharmacology122:198-201.
4. Baruch I, Hemsley D, Gray JA (1988a). Differential performance of acute and chronic schizophrenics in a latent inhibition task.JNerv Ment Dis176: 598-606.
5. Baruch I, Hemsley DR, Gray JA (1988b).Latent inhibition and ‘psychotic proneness’ in normal subjects.Perspect Indiv Differ9:777-783.
6. Braunstein-Bercovitz H, Lubow RE (1998). Are high schizotypal normal participants distractible or limited in attentionalresources? A study of latent inhibition as a function of maskingtask load and schizotypy.J Abnorm Psychol107: 659-670.
7. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through themechanism of action of clozapine.Neuropsychopharmacology13:177-213.
8. Cassaday HF, Hodges H, Gray JA (1993a). The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat.Psychopharmacology7: 63-71.
9. Cassaday HJ, Mitchell SN, Williams JH, Gray JA (1993b). 5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition.Behav Neurol Biol59: 194-207.
10. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988). Haloperidol enhancement of latent inhibition: relation totherapeutic action?Biol Psychiatry23: 746-749.
11. Coutureau E, Gosselin O, Di Scala G (2000). Restoration of latent inhibition by olanzapine but not haloperidol in entorhinalcortex-lesioned rats.Psychopharmacology150: 226-232.
12. De la Casa LG, Ruiz G, Lubow RE (1993).Latent inhibition and recall/recognition of irrelevant stimuli as a function of pre-exposure duration in high and low psychotic-prone normals.BrJ Psychol84: 119-132.
13. Della Casa V, Hofer I, Weiner I, Feldon J (1999). Effects of smoking status and schizotypy on latent inhibition.J Psychopharmacol13:45-57.
14. Dunn LA, Atwater GE, Kilts CD (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of ananimal behavioral model of clinical drug action.Psychopharma-cology112: 315-323.
15. Feldon J, Weiner I (1991). The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpirideenhance rats’ ability to ignore irrelevant stimuli.Biol Psychiatry29: 635-646.
16. Gaisler I, Weiner I (2001). The effect of MK-801 on latent inhibition are selectively reversed by clozapine but nothaloperidol.Biol Psychiatry2: 175.
17. Gosselin G, Oberling P, Di Scala G (1996). Antagonism of amphetamine-induced disruption of latent inhibition by theatypical antipsychotic olanzapine in rats.Behav Pharmacol7:820-826.
18. Gray NS, Hemsley DR, Gray JA (1992a).Abolition of latent inhibition in acute, but not chronic, schizophrenics.NeurolPsychiatr Brain Res1: 83-89.
19. Gray JA, Moran PM, Grigoryan G, Peters SL, Young AMJ, Joseph MH (1997). Latent inhibition: the nucleus accumbens connectionrevisited.Behav Brain Res88: 27-34.
20. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray, JA (1992b).Abolition of latent inhibition by a single low dose ofamphetamine in man.Psychopharmacology107: 425-430.
21. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995). Latent inhibition in drug naive schizophrenics: relationship to durationof illness and dopamine D2 binding using SPET.Schizophr Res17: 95-107.
22. Ichikawa J, Meltzer HY (1999).Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and theaction of typical and atypical antipsychotic drugs.Eur ArchPsychiatry ClinNeurosci249: 90-8.
23. Ichikawa J, Meltzer HY (2000). The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopaminerelease in rat striatum and nucleus accumbens.Brain Res858:252-263.
24. Joseph MH, Peters SL, Moran PM, Grigoryan GA, Young AM, Gray JA (2000). Modulation of latent inhibition in the rat by altereddopamine transmission in the nucleus accumbens at the time ofconditioning.Neuroscience 101: 921-930.
25. Killcross AS, Dickinson A, Robbins TW (1994a). Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentionaldysfunction. Psychopharmacology115: 185-195.
26. Killcross AS, Dickinson A, Robbins TW (1994b). Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversive-ly—and appetitively—motivated paradigms: evidence for dopamine-reinforcer interactions.Psychopharmacology115: 196-205.
27. Kinon BJ, Lieberman JA (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis.Psychopharmacology124:2-34.
28. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993). Interaction of antipsychotic drugs with neurotransmitterreceptor sitesin vitroandin vivoin relation to pharmacologicaland clinical effects—role of 5HT(2) receptors.Psychopharmacology112: S40-S54.
29. Lorden JF, Rickert EJ, Berry DW (1983). Forebrain monoamines and associative learning: I. Latent inhibition and conditionedinhibition.Behav Brain Res9: 181-199.
30. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pK values.J PharmacolExpTher251: 238-246.
31. Meltzer HY, Nash JF (1991). Effects of antipsychotic drugs on serotonin receptors.Pharmacol Rev43: 587-604.
32. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996).Effects of clozapine on latent inhibition in the rat.BehavPharmacol7: 4248.
33. Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model ofschizophrenia.Brain Res Rev33: 275-307.
34. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model ofschizophrenia.Br J Pharmacol116: 2531-7.
35. Peters SL, Joseph MH (1993). Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioningrather than pre-exposure.BehavPharmacol4: 183-186.
36. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand Met al(2001). Clinical features of latent inhibition inschizophrenia.Schizophr Res51: 149-161.
37. Sams-Dodd F (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test.BehavPharmacol8: 196-215.
38. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage ASet al(1996). Risperidone compared withnew and reference antipsychotic drugs:in vitroandin vivoreceptor binding.Psychopharmacology124: 57-73.
39. Schotte A, Janssen PF, Megens AA, Leysen JE (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine andhaloperidol, measuredex vivoby quantitative autoradiography.Brain Res631: 191-202.
40. Shadach E, Feldon J, Weiner I (1999). Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs.Int J Neuropsychopharmacol2: 283-291.
41. Shadach E, Gaisler I, Schiller D, Weiner I (2000). The latent inhibition model dissociates between clozapine, haloperidol, andritanserin.Neuropsychopharmacology23: 151-161.
42. Solomon P, Nichols GL, Kiernan JMI, Kamer RS, Kaplan LJ (1980). Differential effects of lesions in medial and dorsal raphe of therat: latent inhibition and septo-hippocampal serotonin levels.JComp PhysiolPsychol94: 145-154.
43. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA 1996. Latent inhibition in schizophrenia.Schizophr Res20:91-103.
44. Thornton JC, Dawe S, Lee C, Capstick C, Corr PJ, Cotter Pet al(1996). Effects of nicotine and amphetamine on latent inhibitionin human subjects.Psychopharmacology127: 164-173.
45. Trimble KM, Bell R, King DJ (1997).Enhancement of latent inhibition in the rat by the atypical antipsychotic agentremoxipride.Pharmacol Biochem Behav56: 809-816.
46. Trimble KM, Bell R, King DJ (1998).Enhancement of latent inhibition in the rat at a high dose of clozapine.J Psychopharmacology12: 215-219.
47. Vaitl D, Lipp V (1997). Latent inhibition and autonomic res-ponses: a psycholophysiological approach.Behav Brain Res88: 85-94.
48. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994). Antagonism of amphetamine-induced disruption of latentinhibition in rats by haloperdiol and ondansetron—implicationsfor a possible antipsychotic action of ondansetron.Psychopharmacology114: 657-664.
49. Weiner I (1990). Neural substrates of latent inhibition: the switching model.Psychol Bull108: 442-461.
50. Weiner I (2000).The latent inhibition model of schizophrenia. In: Myslobodsky MS, Weiner I (eds).Contemporary Issues inModeling Psychopathology. Kluwer Academic Publishers: Boston. pp 197-230.
51. Weiner I (in press). The "two-headed" latent inhibition model of schizophrenia: Modeling positive and negative symptoms andtheir treatment.Psychopharmacology.
52. Weiner I (2001).Latent inhibition. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P (eds).Current Protocols inNeuroscience.John Wiley & Sons: New York.
53. Weiner I, Feldon J (1987).Facilitation of latent inhibition by haloperidol.Psychopharmacology91: 248-253.
54. Weiner I, Feldon J (1997). The switching model of latent inhibition: an update of neural substrates.Behav Brain Res88:11-25.
55. Weiner I, Feldon J, Katz Y (1987). Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.Pharmacol Biochem Behav26: 241-246.
56. Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D (2000). Screening of antipsychotic drugs in animal models.DrugDev Res50: 235-249.
57. Weiner I, Gal G, Rawlins JN, Feldon J (1996a). Differential involvement of the shell and coresubterritories of the nucleusaccumbens in latent inhibition and amphetamine-inducedactivity.Behav Brain Res81: 123-33.
58. Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronicamphetamine in rats.Psychopharmacology83: 194-199.
59. Weiner I, Lubow RE, Feldon J (1988). Disruption of latent inhibition by acute administration of low doses of amphetamine.Pharmacol Biochem Behav30: 871-878.
60. Weiner I, Shadach E, Barkai R, Feldon J (1997). Haloperidol- and clozapine-induced enhancement of latent inhibition with ex-tended conditioning: implications for the mechanism of actionof neuroleptic drugs. Neuropsychopharmacology16: 42-50.
61. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996b). The latent inhibition model of schizophrenia: further validationusing the atypical neuroleptic, clozapine.Biol Psychiatry40:834-43.
62. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JNP (1997). Haloperidol enhances latent inhibition invisual tasks in healthy people.Psychopharmacology133:262-268.
63. Williams JH, Wellman NA, Geaney DP, Feldon J, Rawlins JN, Cowen PJ (1996). Anti-psychotic drug effects in a model ofschizophrenic attentional disorder: a randomised trial of theeffects of haloperidol on latent inhibition in healthy people.BiolPsychiatry40: 1135-1143.
64. Yee BK, Feldon J, Rawlins JNP (1995). Latent inhibition in rats is abolished by NMDA induced neuronal loss in the retro-hippocampal region but this lesion effect can be prevented bysystemic haloperidol treatment.BehavNeurosci109: 227-240.
65. Zuckerman L, Joel D, Weiner I (2001). Nucleus accumbens core lesion produces persistent latent inhibition which is reversed byclozapine but not haloperidol.Biol Psychiatry2: S36.